Elez, E., Kopetz, S., Tabernero, J., Bekaii-Saab, T., Taieb, J., Yoshino, T., Manji, G., Fernandez, K., Abbattista, A., Zhang, X., & Morris, V. K. (2024). SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC. Future Oncology, 20(11), 653–663. https://doi.org/10.2217/fon-2022-1249